旅行者下痢症(Traveler’s Diarrhea)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Traveler’s Diarrhea Overview 7
Therapeutics Development 8
Pipeline Products for Traveler’s Diarrhea – Overview 8
Pipeline Products for Traveler’s Diarrhea – Comparative Analysis 9
Traveler’s Diarrhea – Therapeutics under Development by Companies 10
Traveler’s Diarrhea – Therapeutics under Investigation by Universities/Institutes 11
Traveler’s Diarrhea – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Traveler’s Diarrhea – Products under Development by Companies 15
Traveler’s Diarrhea – Products under Investigation by Universities/Institutes 16
Traveler’s Diarrhea – Companies Involved in Therapeutics Development 17
Chiesi Farmaceutici SpA 17
Cosmo Pharmaceuticals S.p.A 18
GlycoVaxyn AG 19
Nippon Shinyaku Co., Ltd. 20
Prokarium Ltd. 21
Scandinavian Biopharma Holding AB 22
Sigmoid Pharma Limited 23
Traveler’s Diarrhea – Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
ACE-527 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ACE-920 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Etvax – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GVXNSD-133 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Helicobacter pylori [Hel-305] (multivalent) vaccine – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
INX-201 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
prulifloxacin – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
rifamycin – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Typhetec – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler’s Diarrhea – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Traveler’s Diarrhea – Recent Pipeline Updates 47
Traveler’s Diarrhea – Discontinued Products 50
Traveler’s Diarrhea – Product Development Milestones 51
Featured News & Press Releases 51
Oct 04, 2013: Santarus Announces Presentation of Phase III Data for Rifamycin SV MMX in Travelers’ Diarrhea 51
Sep 11, 2012: Santarus Announces Positive Top-Line Phase III Results For Rifamycin SV MMX In Travelers’ Diarrhea 52
Aug 17, 2011: TD Vaccines To Present ACE527 Phase II Data At Sachs 11th Annual Biotech In Europe 53
Sep 14, 2009: Data From Optimers Second Phase III Study of Prulifloxacin Presented At Annual Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC) 53
Sep 02, 2009: Optimer Pharmaceuticals Announces Presentations Of Additional Phase III Prulifloxacin Data At Upcoming ICAAC Annual Meeting 54
Feb 26, 2009: Optimer Pharmaceuticals Announces Publication In Peer-Reviewed Journal About Prulifloxacins Antibacterial Activity Against Infectious Diarrhea Producing Bacteria 55
Feb 24, 2009: Optimer Pharmaceuticals Announces Positive Results From Second Phase III Study Of Prulifloxacin For Infectious Diarrhea In Travelers 55
Oct 20, 2008: Data from Optimer Pharmaceuticals Prulifloxacin Phase III Trial In Travelers Diarrhea Presented At ICAAC/IDSA Annual Meeting 56
Sep 02, 2008: Optimer Pharmaceuticals Completes Enrollment In Second Prulifloxacin Phase III Clinical Trial 57
Jul 16, 2008: Optimer Pharmaceuticals Announces Positive Results In Prulifloxacin Phase III Study 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59